These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 11909981)

  • 81. Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine.
    Youdim MB; Gassen M; Gross A; Mandel S; Grünblatt E
    J Neural Transm Suppl; 2000; (58):83-96. PubMed ID: 11128615
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Neuroprotective therapies.
    Simon DK; Standaert DG
    Med Clin North Am; 1999 Mar; 83(2):509-23, viii. PubMed ID: 10093591
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Therapy of Parkinson's disease--up to date].
    Murata M
    Rinsho Shinkeigaku; 2008 Nov; 48(11):986-8. PubMed ID: 19198140
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Curcumin: a potential neuroprotective agent in Parkinson's disease.
    Mythri RB; Bharath MM
    Curr Pharm Des; 2012; 18(1):91-9. PubMed ID: 22211691
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Poetic talent unmasked by treatment of Parkinson's disease.
    Schrag A; Trimble M
    Mov Disord; 2001 Nov; 16(6):1175-6. PubMed ID: 11748756
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Dopamine: Agonists and Neurodegenerative Disorders.
    Khanam S; Siddique YH
    Curr Drug Targets; 2018; 19(14):1599-1611. PubMed ID: 29149825
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Design, Synthesis, and Pharmacological Characterization of Carbazole Based Dopamine Agonists as Potential Symptomatic and Neuroprotective Therapeutic Agents for Parkinson's Disease.
    Elmabruk A; Das B; Yedlapudi D; Xu L; Antonio T; Reith MEA; Dutta AK
    ACS Chem Neurosci; 2019 Jan; 10(1):396-411. PubMed ID: 30301349
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [Pharmacological profiles and clinical effects of ropinirole hydrochloride (ReQuip)].
    Arai H; Minami J
    Nihon Yakurigaku Zasshi; 2007 Oct; 130(4):313-9. PubMed ID: 17938518
    [No Abstract]   [Full Text] [Related]  

  • 89. Peripheral markers of apoptosis in Parkinson's disease: the effect of dopaminergic drugs.
    Blandini F; Mangiagalli A; Cosentino M; Marino F; Samuele A; Rasini E; Fancellu R; Martignoni E; Riboldazzi G; Calandrella D; Frigo GM; Nappi G
    Ann N Y Acad Sci; 2003 Dec; 1010():675-8. PubMed ID: 15033810
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Neuroprotection in Parkinson's disease: an elusive goal.
    Koller WC; Cersosimo MG
    Curr Neurol Neurosci Rep; 2004 Jul; 4(4):277-83. PubMed ID: 15217541
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Preventive treatments to slow substantia nigra damage and Parkinson's disease progression: A critical perspective review.
    Bjørklund G; Dadar M; Anderson G; Chirumbolo S; Maes M
    Pharmacol Res; 2020 Nov; 161():105065. PubMed ID: 32652199
    [TBL] [Abstract][Full Text] [Related]  

  • 92. PPAR-γ: therapeutic prospects in Parkinson's disease.
    Carta AR
    Curr Drug Targets; 2013 Jun; 14(7):743-51. PubMed ID: 23469878
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Neuroprotection for Parkinson's disease: a new approach for a new millennium.
    Drukarch B; van Muiswinkel FL
    Expert Opin Investig Drugs; 2001 Oct; 10(10):1855-68. PubMed ID: 11772291
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Mitochondrial dysfunction in Parkinson's disease.
    Greenamyre JT; MacKenzie G; Peng TI; Stephans SE
    Biochem Soc Symp; 1999; 66():85-97. PubMed ID: 10989660
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Effect of Flavonoids against Parkinson's Disease.
    Varshney H; Siddique YH
    Cent Nerv Syst Agents Med Chem; 2024; 24(2):145-165. PubMed ID: 38305395
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Progress of Pharmacological Approaches in Parkinson's Disease.
    Zeuner KE; Schäffer E; Hopfner F; Brüggemann N; Berg D
    Clin Pharmacol Ther; 2019 May; 105(5):1106-1120. PubMed ID: 30661251
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Microglial ion channels as potential targets for neuroprotection in Parkinson's disease.
    Richardson JR; Hossain MM
    Neural Plast; 2013; 2013():587418. PubMed ID: 24288626
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality.
    Marsden CD; Olanow CW
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S189-96. PubMed ID: 9749592
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Dopamine D3 agonists in the treatment of Parkinson's disease.
    Das B; Modi G; Dutta A
    Curr Top Med Chem; 2015; 15(10):908-26. PubMed ID: 25832718
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Melatonin as a neuroprotective agent in the rodent models of Parkinson's disease: is it all set to irrefutable clinical translation?
    Singhal NK; Srivastava G; Agrawal S; Jain SK; Singh MP
    Mol Neurobiol; 2012 Feb; 45(1):186-99. PubMed ID: 22198804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.